Mary Wilson
Well-known member
11/26/21 10:30 AM EST
BY SARAKSHI RAI
BioNTech is studying the new COVID-19 variant that emerged in South Africa and said it will know in two weeks if the vaccine it developed with Pfizer is effective against it, The Financial Times reported.
The German company said it is testing the B.1.1.529 variant to determine if its vaccine would have to be reworked, noting the new variant "differs significantly from previously observed variants."
"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," a BioNTech spokesperson told Reuters.
https://thehill.com/policy/healthca...tech-says-it-will-know-vaccines-effectiveness
BY SARAKSHI RAI
BioNTech is studying the new COVID-19 variant that emerged in South Africa and said it will know in two weeks if the vaccine it developed with Pfizer is effective against it, The Financial Times reported.
The German company said it is testing the B.1.1.529 variant to determine if its vaccine would have to be reworked, noting the new variant "differs significantly from previously observed variants."
"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," a BioNTech spokesperson told Reuters.
https://thehill.com/policy/healthca...tech-says-it-will-know-vaccines-effectiveness